The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...

The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...

Investing.com -- Summit Therapeutics Inc. (NASDAQ:SMMT) stock rose 7% Thursday morning after the U.S. Food and Drug ...

Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C–mutated advanced non-small cell lung cancer: A systematic review and meta-analysis. This is an ASCO Meeting ...

“This case challenges current paradigms, demonstrating that amivantamab monotherapy can effectively target rare EGFR mutations, achieve durable extracranial and CNS disease control, and potentially ...